A detailed history of Virtus ETF Advisers LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 52,865 shares of BCRX stock, worth $395,958. This represents 0.2% of its overall portfolio holdings.

Number of Shares
52,865
Previous 52,865 -0.0%
Holding current value
$395,958
Previous $326,000 23.01%
% of portfolio
0.2%
Previous 0.17%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.13 - $6.79 $26,398 - $43,401
-6,392 Reduced 10.79%
52,865 $326,000
Q1 2024

May 15, 2024

BUY
$4.89 - $7.65 $41,692 - $65,223
8,526 Added 16.81%
59,257 $301,000
Q4 2023

Feb 15, 2024

BUY
$4.98 - $6.77 $61,801 - $84,015
12,410 Added 32.38%
50,731 $303,000
Q3 2023

Nov 07, 2023

SELL
$6.71 - $7.92 $33,261 - $39,259
-4,957 Reduced 11.45%
38,321 $271,000
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $109,320 - $138,378
15,707 Added 56.97%
43,278 $304,000
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $3,850 - $5,742
485 Added 1.79%
27,571 $229,000
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $22,743 - $30,757
2,166 Added 8.69%
27,086 $310,000
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $3,927 - $5,390
364 Added 1.48%
24,920 $314,000
Q2 2022

Aug 12, 2022

SELL
$7.89 - $17.88 $63,009 - $142,789
-7,986 Reduced 24.54%
24,556 $260,000
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $49,773 - $68,827
4,452 Added 15.85%
32,542 $451,000
Q3 2021

Nov 15, 2021

SELL
$14.21 - $17.65 $36,647 - $45,519
-2,579 Reduced 8.41%
28,090 $404,000
Q2 2021

Aug 10, 2021

SELL
$9.5 - $17.24 $44,289 - $80,372
-4,662 Reduced 13.2%
30,669 $485,000
Q1 2021

May 17, 2021

BUY
$7.37 - $13.61 $4,598 - $8,492
624 Added 1.8%
35,331 $359,000
Q4 2020

Feb 12, 2021

SELL
$3.37 - $8.61 $125,151 - $319,749
-37,137 Reduced 51.69%
34,707 $259,000
Q3 2020

Nov 13, 2020

SELL
$3.43 - $5.53 $33,614 - $54,194
-9,800 Reduced 12.0%
71,844 $247,000
Q2 2020

Aug 05, 2020

SELL
$1.9 - $5.61 $74,886 - $221,112
-39,414 Reduced 32.56%
81,644 $389,000
Q1 2020

May 14, 2020

SELL
$1.6 - $4.11 $28,257 - $72,586
-17,661 Reduced 12.73%
121,058 $242,000
Q4 2019

Feb 13, 2020

BUY
$1.59 - $3.45 $102,055 - $221,441
64,186 Added 86.12%
138,719 $479,000
Q3 2019

Nov 12, 2019

SELL
$2.5 - $3.73 $10,377 - $15,483
-4,151 Reduced 5.28%
74,533 $214,000
Q2 2019

Aug 13, 2019

BUY
$2.91 - $9.15 $137,954 - $433,774
47,407 Added 151.57%
78,684 $298,000
Q1 2019

May 14, 2019

SELL
$7.38 - $9.72 $29,689 - $39,103
-4,023 Reduced 11.4%
31,277 $255,000
Q4 2018

Feb 05, 2019

SELL
$6.51 - $9.6 $313,586 - $462,432
-48,170 Reduced 57.71%
35,300 $285,000
Q3 2018

Nov 14, 2018

SELL
$5.52 - $7.99 $329,334 - $476,699
-59,662 Reduced 41.68%
83,470 $637,000
Q2 2018

Aug 10, 2018

SELL
$4.6 - $6.52 $50,668 - $71,817
-11,015 Reduced 7.15%
143,132 $820,000
Q1 2018

May 14, 2018

BUY
$4.35 - $5.82 $361,337 - $483,444
83,066 Added 116.86%
154,147 $735,000
Q4 2017

Feb 14, 2018

BUY
$4.16 - $5.33 $59,105 - $75,728
14,208 Added 24.98%
71,081 $349,000
Q3 2017

Nov 14, 2017

BUY
$4.1 - $5.97 $21,328 - $31,055
5,202 Added 10.07%
56,873 $298,000
Q2 2017

Aug 14, 2017

BUY
N/A
51,671
51,671 $287,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.